Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis HCK in erythropoietin/PI3K pathway

Full text
Author(s):
Show less -
Roversi, Fernanda Marconi ; Pericole, Fernando Vieira ; Machado-Neto, Joao Agostinho ; Santos Duarte, Adriana da Silva ; Longhini, Ana Leda ; Corrocher, Flavia Adolfo ; Palodetto, Bruna ; Ferro, Karla Priscila ; Rosa, Renata Giardini ; Baratti, Mariana Ozello ; Verjovski-Almeida, Sergio ; Traina, Fabiola ; Molinari, Alessio ; Botta, Maurizio ; Olalla Saad, Sara Teresinha
Total Authors: 15
Document type: Journal article
Source: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE; v. 1863, n. 2, p. 450-461, FEB 2017.
Web of Science Citations: 3
Abstract

New drug development for neoplasm treatment is nowadays based on molecular targets that participate in the disease pathogenesis and tumor phenotype. Herein, we describe a new specific pharmacological hematopoietic cell kinase (HCK) inhibitor (iHCK-37) that was able to reduce PI3K/AKT and MAPK/ERK pathways activation after erythropoietin induction in cells with high HCK expression: iHCK-37 treatment increased leukemic cells death and, very importantly, did not affect normal hematopoietic stem cells. We also present evidence that HCK, one of Src kinase family (SFK) member, regulates early-stage erythroid cell differentiation by acting as an upstream target of a frequently deregulated pathway in hematologic neoplasms, PI3K/AKT and MAPK/ERK. Notably, HCK levels were highly increased in stem cells from patients with some diseases, as Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML), that are associated with ineffective erythropoiesis These discoveries support the exploration of the new pharmacological iHCK-37 in future preclinical and clinical studies. (C) 2016 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 11/22376-7 - Investigation deregulated pathways in myelodysplasia and acute leukemia from previous results obtained using microarray
Grantee:Fernanda Marconi Roversi
Support Opportunities: Scholarships in Brazil - Post-Doctoral